AstraZeneca paid partner Pozen $10 million in milestone dues after Pozen's application for arthritis drug Vimovo was accepted for FDA review. Pozen is seeking to market Vimovo for patients with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis who are at risk of developing gastric ulcers if they take other arthritis treatments.

Related Summaries